Recovery and purification process development for monoclonal antibody production

mAbs

Volumn 2, Issue 5, 2010, Pages 480-499

  Liu, Hui F ^a   Ma, Junfen ^a   Winter, Charles ^a   Bayer, Robert ^a  

^a GENENTECH INC   (United States)

Author keywords

Chromatography; Filtration; Membrane; Monoclonal antibody; Platform process; Purification; Recovery

Indexed keywords

MONOCLONAL ANTIBODY; PROTEIN A;

AFFINITY CHROMATOGRAPHY; ANION EXCHANGE CHROMATOGRAPHY; ANTIBODY PRODUCTION; CELL DENSITY; CERAMIC HYDROXYAPATITE CHROMATOGRAPHY; CHROMATOGRAPHY; FILTRATION; FLOCCULATION; HUMAN; HYDROPHOBICITY; ION EXCHANGE CHROMATOGRAPHY; MEMBRANE CHROMATOGRAPHY; MICROFILTRATION; MULTIMODAL CHROMATOGRAPHY; NONHUMAN; PRECIPITATION; PURIFICATION; REVIEW; ULTRAFILTRATION; VIRUS FILTRATION;

ANIMALS; ANTIBODIES, MONOCLONAL; CHO CELLS; CHROMATOGRAPHY; CRICETINAE; CRICETULUS; REPRODUCIBILITY OF RESULTS; TECHNOLOGY, PHARMACEUTICAL;

EID: 77958589701     PISSN: 19420862     EISSN: None     Source Type: Journal    
DOI: 10.4161/mabs.2.5.12645     Document Type: Review

References (135)

1. Reichert JM, Valge-Archer VE. Development trends for monoclonal antibody cancer therapeutics. Nat Rev Drug Discov 2007; 6:349-56.
2. Fahrner RL, Knudsen HL, Basey CD, Galan W, Feuerhelm D, Vanderlaan M, et al. Industrial purification of pharmaceutical antibodies: development, operation and validation of chromatography processes. Biotechnol Genet Eng Rev 2001; 18:301-27.
3. Birch JR, Racher JR. Antibody production. Adv Drug Delivery Rev 2006; 58:671-85.
4. Kempken R, Pressman A, Berthold W. Assessment of a disc stack centrifuge for use in mammalian cell separation. Biotechnol Bioeng 1995; 46:132-8.
5. rd International IBC Recovery and Purification Conference, San Diego, CA 2002.
6. th ACS National Meeting, New Orleans, LA 2003.
7. Altena FW, Belfort G. Lateral migration of spherical particles in porous flow channels: application to membrane filtration. Chem Eng Sci 1984; 39:343-55.
8. Davis RH, Leighton DT. Shear-induced transport of a particle layer along a porous wall. Chem Eng Sci 1987; 42:275-81.
9. Drew DA, Schonberg JA, Belfort G. Lateral inertial migration of a small sphere in fast laminar flow through a membrane duct. Chem Eng Sci 1991; 46:3219-24.
10. Romero CA, Davis RH. Global model of crossflow microfiltration based on hydrodynamic particle diffusion. J Membr Sci 1988; 39:157-85.
11. Bender J, Brown A, Winter C. Scale-up of a disc stack centrifuge for CHO harvest, Downstream Gab '02 abstracts, Amersham Biosciences 2002; 10-1.
12. Hutchison N, Bingham N, Murrell N, Farid S, Hoare M. Shear stress analysis of mammalian cell suspensions for prediction of industrial centrifugations and its verification. Biotechnol Bioeng 2006; 95:483-91. (Pubitemid 44495383)
13. Iammarino M, Nti-Gyabaah J, Chandler M, Roush D, Goklen K. Impact of cell density and viability on primary clarification of mammalian cell broth. Bioprocess Int 2007; 5:38-50.
14. th International Waterside Conference 2009; South San Francisco CA.
15. Schmidt M. Antibody degradation (disulfide reduction) in a CHO production process. IBC Antibody Development & Production Conference 2009; Carlsbad CA.
16. Knight RA, Ostreicher EA. Charge-modified filter media. Filtration in the biopharmaceutical industry Meltez TH, Jornitz MW, Editors. Marcel Dekker, Inc.: New York, NY 1998; 95-125.
17. Tipton B, Boose JA, Larsen W, Beck J, O'Brien T. Retrovirus and parvovirus clearance from an affinity column product using adsorptive depth filtration. BioPharm Int 2002; 15:43-50. (Pubitemid 35006309)
18. Gerba CP, Hou K. Endotoxin removal by charge-modified filters. Appl Environ Microbiol 1985; 50:1375-7.
19. Hou K, Gerba CP, Goyal SM, Zerda KS. Capture of latex beads, bacteria, endotoxin and viruses by charge-modified filters. Appl Environ Microbiol 1980; 40:892-6. (Pubitemid 11215931)
20. vanHolten RW, Autenrieth SM. Evaluation of depth filtration to remove prion challenge from an immunoglobulin preparation. Vox Sang 2003; 85:20-4.
21. Dorsey N, Eschrich J, Cyr G. The role of charge in the retention of DNA by charged cellulose-based depth filters. BioPharm 1997; 10:46-9. (Pubitemid 27064418)
22. Charlton HR, Relton JM, Slater NKH. Characterisation of a generic monoclonal antibody harvesting system for adsorption of DNA by depth filters and various membranes. Bioseparation 1999; 8:281-91.
23. Yigzaw Y, Piper R, Tran M, Shukla AA. Exploitation of the adsorptive properties of depth filters for host cell protein removal during monoclonal antibody purification. Biotechnology Progress 2006; 22:288-96. (Pubitemid 43221555)
24. Aunins JG, Wang DI. Induced flocculation of animal cells in suspension culture. Biotechnol Bioeng 1989; 34:629-38.
25. Salt DE, Hay O, Thomas ORT, Hoare M, Dunnill P. Selective flocculation of cellular contaminants from soluble proteins using polyethyleneimine: a study of several organisms and polymer molecular weights. Enzyme Microb Technol 1995; 17:107-13.
26. Riske F, Schroeder J, Belliveau J, Kang X, Kutzko J, Menon MK. The use of chitosan as a flocculant in mammalian cell culture dramatically improves clarification throughput without adversely impacting monoclonal antibody recovery. J Biotechnol 2007; 128:813-23. (Pubitemid 46341481)
27. Romero J. Disc stack centrifugation 29,000 L clarification scale-up evaluation: harvest optimization for combined cell removal and purification. BioProcess International Conference 2007; Boston MA.
28. Coffman J, Shpritzer R, Vicik S. Flocculation of antibody producing mammalian cells with precipitating solutions of soluble cations and anions. Recovery of Biological product XII 2006; Litchfield AZ.
29. Hashimoto M, Yamamoto T, Kawachi T, Kuwashima J, Kitaoka H. Low molecular weight chitosans for the removal of nucleic acids and/or endotoxins from liquid samples on a small or large scale. EP Patent 240348. 19931027.
30. Hughes J, Ramsden DK, Symes KC. The flocculation of bacteria using cationic synthetic flocculants and chitosan. Biotechnol Tech 1990; 4:55-60.
31. Persson I, Lindman B. Flocculation in biotechnology and separation systems. In: Flocculation of cell debris for improved separation by centrifugation. Elsevier Science Publishers B.V.: Amsterdam 1987; 457-66.
32. Weir S, Ramsden DK, Hughes J, LeThomas F. The flocculation of yeast with chitosan in complex fermentation media: the effect of biomass concentration and mode of flocculant addition. Biotechnol Tech 1993; 7:199-204.
33. Ghose S, Hubbard B, Cramer SM. Binding capacity differences for antibodies and Fc-fusion proteins on protein A chromatographic materials. Biotechnol Bioeng 2007; 96:768-79.
34. Fahrner RL, Whitney DH, Vanderlaan M, Blank GS. Performance comparison of protein A affinity-chromatography sorbents for purifying recombinant monoclonal antibodies. Biotechnol Appl BioChem 1999; 30:121-8. (Pubitemid 29472172)
35. O'Leary RM, Feuerhelm D, Peers D, Xu Y, Blank GS. Determining the useful lifetime of chromatography resins. BioPharm Int 2001; 10-8.
36. Carter-Franklin JN, Victa C, McDonald P, Fahrner R. Fragments of protein A eluted during protein A affinity chromatography. J Chromatogr A 2007; 1163:105-11. (Pubitemid 47247702)
37. Blank G. Protein purification. United States Patent No: US 6797814 2004.
38. Breece T, Fahrner R, Gorrell JR, Lazzareschi KP, Lester P, Peng D. Protein purification. United States Patent No: US 6870034 B2 2005.
39. Arakawa T, Philo JS, Tsumoto K, Yumioka R, Ejimac D. Elution of antibodies from a Protein A column by aqueous arginine solutions. Protein Expr Purif 2004; 36:244-8. (Pubitemid 38893161)
40. Shukla AA, Hinckley PJ, Gupta P, Yigzaw Y, Hubbard B. Strategies to address aggregation during protein A chromatography. Bioprocess Int 2005; 3:36-44.
41. Ghose S, Allen M, Hubbard B, Brooks C, Cramer SM. Antibody variable region interactions for the development of generic purification process. Biotechenol Bioeng 2005; 92:665-73.
42. Gronberg A, Monié E, Murby M, Rodrigo G, Wallby E, Johansson H. A strategy for developing a monoclonal antibody purification platform. Bioprocess Int 2007; 5:48-55.
43. Wan M. Process mapping - A necessary prelude for process changing. IBC's BioProcess International Conference 2004; Boston MA.
44. Curtis S, Lee K, Blank GS, Brorson K, Xu Y. Generic/matrix evaluation of SV40 clearance by anion exchange chromatography in flow-through mode. Biotechnol Bioeng 2003; 84:179-86. (Pubitemid 37176329)
45. Norling LA, Lute S, Emery R, Khuu W, Voisard M, Xu Y, et al. Impact of multi re-use of anion exchange chromatography media on virus removal. J Chromatogr A 2005; 1069:79-89. (Pubitemid 40380629)
46. Zhou JX. Development of future downstream process for commercial monoclonal antibody production. Presentation at Asia bioLogic 2007; Beijing, China.
47. Liu H, Kellogg T. Development of an anion exchange chromatographic process in bind-elute and bind-washout modes. BPI International Conference & Exhibition 2008; Anaheim, CA.
48. Liu H, Tang K. A method for the removal of aggregate proteins from recombinant samples using ion exchange chromatography. Patent application WO 2005/077130 A2 2005.
49. th International Antibody Production & Downstream Processing 2005; San Diego CA.
50. nd Annual Meeting, Amsterdam, The Netherlands 2005.
51. Kelly BD, Tobler SA, Brown P, Coffman JM, Godavarti R, Iskra T, et al. Weak partitioning chromatography for anion exchange purification of monoclonal antibodies. Biotechnol Bioeng 2008; 101:553-66.
52. Coffman J, Kramarczyk J, Kelley B. High-throughput screening of chromatographic separations: 1. Method development & column modeling. Biotechnol Bioeng 2008; 100:605-18.
53. Kelley B, Switzer M, Booth J, Coffman J. Application of high throughput screening to a Mab purification platform. IBC conference 2005; Boston MA.
54. Harinarayan C, Mueller J, Ljunglof A, Fahrner R, Van Alstine J, van Reis R. An exclusion mechanism in ion exchange chromatography. Biotechnol Bioeng 2006; 95:775-87. (Pubitemid 44867475)
55. Ansaldi DA, Lester P. Separation of polypeptide monomers. United States Patent No: US 6620918 2003.
56. Follman D, Fahrner R. Factorial screening of antibody purification process using three chromatography steps without protein A. J Chromatogr A 2004; 1024: 79-85. (Pubitemid 37532537)
57. Mhatre R, Nashabeh W, Schmalzing D, Yao X, Fuchs M, Whitney D, et al. Purification of antibody Fab fragments by cation-exchange chromatography and pH gradient elution. J Chromatogr A 1995; 707:225-31.
58. Zhou J, Dermawan S, Soloamo F, Flynn G, Stenson R, Tressel T, et al. pH-conductivity bybrid gradient cation-exchange chromatography for process-scale monoclonal antibody purification. J Chromatogr A 2007; 1175:69-80. (Pubitemid 350116830)
59. Porath J. Salt-promoted adsorption: recent developments. J Chromatog 1986; 376:331-41.
60. Guse A, Milton A, Schulze-Koops H, Muller B, Roth E, Simmer B. Purification and analytical characterization of an anti-CD4 monoclonal antibody for human therapy. J Chromatogr A 1994; 661:13-23.
61. Kato Y, Nakamura K, Kitamura T, Hasegawa M, Sasaki H. Hydrophobic interaction chromatography at low salt concentration for the capture of monoclonal antibodies. J Chromatogr A 2004; 1036:45-50.
62. Manzke O, Tesch H, Diehl V, Bohlen H. Single-step purification of bispecific monoclonal antibodies for immunotherapeutic use by hydrophobic interaction chromatography. J Immunol Methods 1997; 208: 65-73.
63. Rinderknecht E, Zapata G. Antibody purification. United States Patent Application 2002/0002271 2002.
64. Burton SC, Harding DRK. Hydrophobic charge induction chromatography: salt independent protein adsorption and facile elution with aqueous buffers. J Chromatogr A 1998; 814:71-81.
65. Yon RJ. Chromatography of lipophilic protein on adsorbents containing mixed hydrophobic and ionic groups. Biochem J 1972; 126:765-7.
66. Guerrier GP, Schwartz W, Boschetti E. New method for the selective capture of antibodies under physiological conditions. Bioseparation 2000; 9:211-21.
67. Schwartz W, Judd D, Wysocki M, Guerrier L, Birck-Wilson E, Boschetti E. Comparison of HCIC with affinity chromatography on protein A for harvest and purification of antibody. J Chromatogr A 2001; 908:251-63.
68. Franklin SG. Removal of aggregate from an IgG 4 product using CHT ceramic hydroxyapatite. BioProcess Int 2003; 1:50-1.
69. Gagnon P, Ng P, Zhen J, Aberin C, He J, Mekosh H, et al. A ceramic hydroxyapatite based purification platform. BioProcess Int 2006; 4:50-60.
70. Brekkan E. Capto™ Adhere - optimization of loading conditions by use of design of experiments. IBC's 18th International Antibody Development & Production 2007; Carlsbad, CA.
71. Bensch M, Wierling PS, von Lieres E, Hubbuch J. High throughput screening of chromatographic phases for rapid process development. Chem Eng Technol 2005; 28:1274-84.
72. Coffman J, Kramarczyk JF, Kelley BD. High-throughput screening of chromatographic separations: I. Method development and column modeling. Biotechnol Bioeng 2008; 100:605-18.
73. Wierling PS, Bogumil R, Knieps-Grunhagen E, Hubbuch J. High-throughput screening of packed-bed chromatography coupled with SELDI-TOF MS analysis: monoclonal antibodies versus host cell protein. Biotechnol Bioeng 2007; 98:440-50.
74. Kramarczyk JF, Kelley BD, Coffman JL. High-throughput screening of chromatographic separations: II. Hydrophobic interaction. Biotechnol Bioeng 2008; 100:707-20.
75. Wensel DL, Kramarczyk JF, Kelley BD, Coffman JL. High-throughput screening of chromatographic separations: III. Monoclonal antibodies on ceramic hydroxyapatite. Biotechnol Bioeng 2008; 100:839-54.
76. Kelley BD, Switzer M, Bastek P, Kramarczyk JF, Molnar K, Yu T, et al. High-throughput screening of chromatographic separations: IV. Ion-exchange. Biotechnol Bioeng 2008; 100:950-63.
77. Roper DK, Lightfoot EN. Separation of biomolecules using adsorptive membranes. J Chromatogr A 1995; 702:3-26.
78. Knudsen HL, Fahrner R, Xu Y, Norling L, Blank G. Membrane ion-exchange chromatography for process-scale antibody purification. J Chromatogr A 2001; 907:145-54.
79. Ghosh R. Protein separation using membrane chromatography: opportunities and challenges. J Chromatogr A 2002; 952:13-27.
80. Phillips M, Moya W, Kozlov M, Yang T. A fundamental understanding of a novel membrane adsorber technology. Recovery of Biological Products XIII 2008; Québec City, Canada.
81. Phillips M, Cormier J, Ferrence J, Dowd C, Kiss R, Lutz H, et al. Performance of a membrane adsorber for trace impurity removal in biotechnology manufacturing. J Chromatogr A 2005; 1078:74-82.
82. Zhou JX, Tressel T, Gottschalk U, Solamo F, Pastor A, Dermawan S, et al. New Q membrane scale-down model for process-scale antibody purification. J Chromatogr A 2006; 1134:66-73. (Pubitemid 44633924)
83. Zhou JX, Tressel T. Basic concepts in Q membrane chromatography for large-scale antibody production. Biotechnol Progr 2006; 22:341-9.
84. vanReis R, Zydney AL. Protein ultrafiltration. in Encyclopedia of Bioprocess Technology-Fermentation, Biocatalysis and Bioseparation. Flickinger MC, Drew SW, Editors. John Wiley & Sons 1999; 2197-214.
85. Tutunjian RS. Ultrafiltration processes in biotechnology, in Principles of Biotechnology: Engineering Considerations. Cooney CL, Humphrey AE, Editors. Pergamon Press: Elmsford, New York 1985; 411-37.
86. vanReis R, Zydney A. Bioprocess membrane technology. J Membr Sci 2007; 297:16-50.
87. vanReis R, Goodrich EM, Yson CL, Frautschy LN, Whiteley R, Zydney AL. Constant Cwall ultrafiltration process control. J Membr Sci 1997; 130:123-40.
88. Luo R, Waghmare R, Krishnan M, Adams C, Poon E, Kahn D. High-concentration UF/DF of a monoclonal antibody. Bioprocess Int 2006; 4:44-6.
89. Winter C, Mulherkar P, Thai B, Liu J, Kanai S, Shire SJ. Formulation strategy and high temperature UF to achieve high concentration rhuMAbs. Recovery of Biological Products XIII 2008; Quebec City, Quebec, Canada.
90. Rajniak P, Tsinontides S, Pham D, Hunke W, Reynolds S, Chern R. Sterilizing filtration - principles and practice for successful scale-up to manufacturing. J Membr Sci 2008; 325:223-37.
91. Dixit M. High-performance sterile filtration. BioProcess Int (Industry Yearbook) 2009; 7:92-3.
92. Millipore Corporation. Data sheet: Millipore express® SHF hydrophilic filters. Lit. No. DS1426EN00.
93. Ebersold MF, Zydney AL. Separation of protein charge variants by ultrafiltration. Biotechnol Progr 2004; 20:543-9.
94. Saksena S, Zydney AL. Effect of solution pH and ionic strength on the separation of albumin from immunoglobulins (IgG) by selective filtration. Biotechnol Bioeng 1994; 43:960-8. (Pubitemid 24234276)
95. vanReis R, Brake JM, Charkoudian J, Burns DB, Zydney AL. High-performance tangential flow filtration using charged membranes. J Membr Sci 1999; 159:133-42.
96. vanReis R, Gadam S, Frautschy LN, Orlando S, Goodrich EM, Saksena S, et al. High performance tangential flow filtration. Biotechnol Bioeng 1997; 56:71-82.
97. Wan Y, Vasan S, Ghosh R, Hale G, Cui Z. Separation of monoclonal antibody alemtuzumab monomer and dimers using ultrafiltration. Biotechnol Bioeng 2005; 90:422-32. (Pubitemid 40779193)
98. vanReis R, Zydney AL. Membrane separations in biotechnology. Curr Opin Biotechnol 2001; 12:208-11.
99. Burns DB, Zydney AL. Effect of solution pH on protein transport through ultrafiltration membranes. Biotechnol Bioeng 1999; 64:27-37. (Pubitemid 29252309)
100. Fahrner R, Follman D, Lebreton B, Van Reis R. Non-affinity purification of proteins. United States Patent 2008; 7323553.
101. Brorson K, Krejci S, Lee K, Hamilton E, Stein K, Xu Y. Bracketed generic inactivation of rodent retroviruses by low pH treatment for monoclonal antibodies and recombinant proteins. Biotechnol Bioeng 2003; 82:321-9. (Pubitemid 36402545)
102. Kern G, Krishnan M. Virus removal by filtration: points to consider. BioPharm Int 2006; 19.
103. FDA. Points to Consider in the Manufacture and Testing of Monoclonal Antibody products for Human Use. Points to Consider in the Manufacture and Testing of Monoclonal Antibody products for Human Use 1997.
104. Carter J, Lutz H. An overview of viral filtration in biopharmaceutical manufacturing. Eur J Parenteral Sci 2002; 7:72-8.
105. Bolton GR, Spector S, LaCasse D. Increasing the capacity of parvovirus-retentive membranes: performance of the viresolve prefilter. Biotechnol Appl Biochem 2006; 43:55-63.
106. th antibody development and production conference 2008; San Diego, CA.
107. Ireland T, Bolton G, Noguchi M. Optimizing virus filter performance with prefiltration. BioProcess Int 2005; 3:44-7.
108. th ACS National Meeting & Exposition 2008; Philadelphia, Pennsylvania.
109. Kuriyel R, Zydney AL. Sterile Filtration and Virus Flitration, in Downstream Processing of Proteins. Desai MA, Editor. Humana Press 2000; 185-94.
110. Morris GM, Rozembersky J, Schwartz L. Validation of Filtration. In: Biopharmaceutical Process Validation. Sofer G, Zabriskie DW, Editors. Marcel Dekker 2000; 213-33.
111. Kelley B, Blank G, Lee A. Downstream Processing of Monoclonal Antibodies: Current Practices and Future Opportunities. In: Process Sacle Purification of Antibodies. Gottschalk U, Editor. John Wiley & Sons, Inc 2009; 1-23.
112. Shukla AA, Hubbard B, Tressel T, Guhan S, Low D. Downstream processing of monoclonal antibodies - Application of platform approaches. J Chromatogr B 2007; 848:28-39.
113. Chen Q. Viral Clearance Design Space for mAb Purification Process. CMC Strategy Forum 2007; www.casss.org/cmc/PDFs/ChenPPSlidesJuly2007.pdf
114. Low D, O'Leary R, Pujar NS. Future of antibody purification. J Chromatogr B 2007; 848:48-63.
115. Gerngross TU. Advances in the production of human therapeutic proteins in yeasts and filamentous fungi. Nat Biotechnol 2004; 11:1409-12.
116. Hellwig S, Drossard J, Twyman RM, Fischer R. Plant cell cultures for the production of recombinant proteins. Nat Biotechnol 2004; 11:1415-22. (Pubitemid 39482861)
117. Nikolov ZL, Woodard SL. Downstream processing of recombinant proteins from transgenic feedstock. Curr Opin Biotechnol 2004; 15:479-86.
118. Przybcien TM, Pujar NS, Steele LM. Alternative bioseparation operations: life beyond packed-bed chromatography. Curr Opin Biotechnol 2004; 15:469-78.
119. Thommes J, Etzel M. Alternatives to chromatographic separations. Biotechnol Progr 2007; 23:42-5.
120. Shan JG, Xia J, Guo YX, Zhang XQ. Flocculation of cell, cell debris and soluble protein with methacryloyloxyethyl trimethylammonium chloride- acrylonitrile copolymer. J Biotechnol 1996; 49:173-8. (Pubitemid 26316252)
121. Fahrner RL, Franklin J, McDonald P, Peram T, Sisodiya V, Victa C. Polyelectrolyte precipitation and purification proteins. US Patent Application 2008; 20080193981.
122. Ramanan S. Presentation to IBC Antibody Development and Production conference 2007.
123. Sumner JB. The isolation and crystallization of the enzyme urease. J Biol Chem 1926; 69:435-41.
124. Flores H, Lin TP, Matthews TC, Pai R, Shahrokh Z. Apo-2 ligand/trail formulations. US patent application 2006; 20060009387.
125. Peters J, Minuth T, Schroder W. Implementation of a crystallization step into the purification process of a recombinant protein. Protein Expression Purif 2005; 39:43-53. (Pubitemid 39648993)
126. Drohan WN, Miekka SI, Griko YV, Forng RY, Stafford RE, Hill CR, et al. Gamma irradiation of intravenous immunoglobulin. Dev Biol 2004; 118:133-8.
127. Hart H, Reid K, Hart W. Inactivation of viruses during ultraviolet light treatment of human intravenous immunoglobulin and albumin. Vox Sang 1993; 64: 82-8.
128. Roberts P, Hope A. Virus inactivation by high intensity broad spectrum pulsed light. J Virol Methods 2003; 110:61-5.
129. Li Q, MacDonald S, Bienek C, Foster PR, MacLeod AJ. Design of a UV-C irradiation process for the inactivation of viruses in protein solutions. Biologicals 2005; 33:101-10.
130. Tran H, Marlowe K, McKenney K, Petrosian G, Griko Y, Burgess W, et al. Functional integrity of intravenous immunoglobulin following irradiation with a virucidal dose of gamma radiation. Biologicals 2004; 32:94-104.
131. Charm SE, Landau S, Williams B, Horowitz B, Prince AM, Pascual D. High temperature short-time heat inactivation of HIV and other viruses in human blood plasma. Vox Sang 1992; 62:12-20.
132. Charm SE, Landau S, Zarrineghbal H, Golden RF. High temperature, short time microwave heating system and method of heating heat-sensitive material. US patent 1995; 5,389,335.
133. Korneyeva M, Hotta J, Lebing W, Rosenthal RS, Franks L, Petteway SR. Enveloped virus inactivation by caprylate: a robust alternative to solvent-detergent treatment in plasma derived intermediates. Biologicals 2002; 30:153-6.
134. Lebing W, Remington KM, Schreiner C, Paul HI. Properties of a new intravenous immunoglobulin (IGIV-C, 10%) produced by virus inactivation with caprylate and column chromatography. Vox Sang 2003; 84:193-201.
135. Kelley B. Very large scale monoclonal antibody purification: the case for conventional unit operations. Biotechnol Progr 2007; 23:995-1008.